Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

ASCO Odds/Ends And Clinical Study Links

Home/Research/ASCO Odds/Ends And Clinical Study Links

ASCO Odds/Ends And Clinical Study Links

A few more quick notes from ASCO before the first of a long running series about ways to improve peripheral neuropathy (PN) starts later today:

Secondary Cancer Risk From Using Revlimid:
Based on the results of this retrospective analysis, Dr. Palumbo concluded that Revlimid ,when used with melphalan, increases the rate of secondary cancers.  The good news is Revlimid does not increase second cancers when used with dexamethasone.

Links To Clinical Studies:
You have been reading about a lot of new, assisting drugs which may help us live longer.  You can use the clinical study search widget, located on the right side of this page near the top.  Or, here is a link to four clinical studies which feature assisting drugs, sponsored by the Mutliple Myeloma Research Foundation (MMRF):

Phase III study comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd)

Phase III study of Perifosine, Bortezomib, and Dexamethasone

Phase III study of Panobinostat or Placebo with Bortezomib and Dexamethasone

Phase III study of Lenalidomide and Dexamethasone with or without Elotuzumab

Carfilzomib may eventually be added to the list of the “big three,”  Thalomid/Revlimid/Velcade.  It is right on the line.  I think of it as more of a “super side-kick drug” or an “assisting drug-squared” or an assisting drug on steroids (Pun intended!)

Feel good and keep smiling!  Pat